Please login to the form below

Not currently logged in
Email:
Password:

New NHS specialist cancer unit

Cancer campaigners welcome policy to invest in the treatment of brain and spinal cord tumours

Cancer charities have welcomed a move by ministers in England to increase investment in specialist cancer care for brain and spinal cord tumours.

Under ministerial proposals, hospitals will be invited to bid to become the first national centre for proton therapy – a cancer treatment that uses radiation to attack cancerous cells while minimising damage to nearby tissue. It works by firing energy into the tumour where electrons damage the DNA of cancerous cells, killing them.

There is just one specialist unit in England and it treats only less complex eye cancers. Clatterbridge on the Wirral uses a low-energy machine that can only be used to reach cancers near the eye. As a result, many patients are forced to seek care abroad.

Proton therapy, which is most commonly used on children and patients with tumours near the most sensitive parts of the brain and spinal cord, is available in the US and other European countries. However, the cost of treatment can be in excess of £100,000.

The new unit in England would treat up to 400 patients each year.

Wendy Fulcher, chairman of cancer charity, Brain Tumour Research, welcomed the news, saying that she hopes the move will "signal a shift in policy for increased funding for brain tumour treatment and research".

19th August 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics